Table 3

The novel predictions of DCPred2

Rank

Drug components

P-value

Common

targets

Reported effective combinations?


10

DB00275; DB00177

Olmesartan; Valsartan

4.35E-05

AGTR1

No

11

DB00275; DB00966

Olmesartan; Telmisartan

4.35E-05

AGTR1

No

12

DB00177; DB00966

Valsartan; Telmisartan

4.35E-05

AGTR1

No

13

DB01248; DB00441

Docetaxel; Gemcitabine

4.83E-05

None

Yes

14

DB00526; DB01248

Oxaliplatin; Docetaxel

4.83E-05

None

No

22

DB00398; DB00112

Sorafenib; Bevacizumab

0.000130406

None

Yes

23

DB00741; DB00860

Hydrocortisone; Prednisolone

0.000130406

None

No

24

DB01132; DB00412

Pioglitazone; Rosiglitazone

0.000130406

PPARG

No

25

DB00480; DB00987

Lenalidomide; Cytarabine

0.000130406

None

No

26

DB00398; DB00002

Sorafenib; Cetuximab

0.000130406

None

No

27

DB00564; DB00776

Carbamazepine; Oxcarbazepine

0.000130406

SCN5A

No

34

DB00762; DB01101

Irinotecan; Capecitabine

0.000260813

None

Yes

35

DB00480; DB01041

Lenalidomide; Thalidomide

0.000260813

PTGS2

Yes


Novel predictions (not reported in DCDB) in the top 35 ranked drug combinations, where only drugs having at least 2 neighbors were included, resulting in 74 positive drug combinations and 1107 random ones.

Xu et al. BMC Systems Biology 2012 6(Suppl 1):S5   doi:10.1186/1752-0509-6-S1-S5

Open Data